Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL445068 | 0.93 | AKR1A1 (1.00) | AKR1A1AKR1B1 | |
| SCHEMBL2099099 | 0.93 | AKR1A1 (1.00) | AKR1A1AKR1B1 | |
| Lidorestat SCHEMBL419032 | 0.90 | AKR1A1 (1.00) | AKR1A1AKR1B1 | |
| Lidorestat SCHEMBL29387869 | 0.90 | AKR1A1 (1.00) | AKR1A1AKR1B1 | |
| SCHEMBL420984 | 0.89 | AKR1A1 (1.00) | AKR1A1AKR1B1 | |
| Lidorestat SCHEMBL6103908 | 0.89 | AKR1A1 (0.98) | AKR1A1AKR1B1 | |
| SCHEMBL420815 | 0.87 | AKR1A1 (1.00) | AKR1A1AKR1B1 | |
| SCHEMBL445833 | 0.87 | AKR1A1 (1.00) | AKR1A1AKR1B1 | |
| SCHEMBL420980 | 0.87 | AKR1A1 (1.00) | AKR1A1AKR1B1 | |
| SCHEMBL419670 | 0.87 | AKR1A1 (1.00) | AKR1A1AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214540-A1 | 3-[(phenyl or benzothiazol-2-yl)methyl]indole-N-acetic acids and esters; analgesics; aldose reductase inhibitors; diabetes complications including cataracts, retinopathy, nephropathy, and neuropathy; side effect reduction | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, LLC | 2008-09-04 | — | — | US | claimed |
| US-20060074114-A1 | Methods of reducing serum glucose and triglyceride levels and for inhibiting angiogenesis using substituted indolealkanoic acids | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, INC. | 2006-04-06 | — | — | US | claimed |
| US-20040235933-A1 | Substituted indolealkanoic acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY LLC | 2004-11-25 | — | — | US | claimed |
| EP-1066283-B1 | SUBSTITUTED INDOLEALKANOIC ACIDS | INST FOR PHARM DISCOVERY INC (US) | 2004-06-23 | — | — | EP | claimed |
| EP-1135124-B1 | ANTIHYPERTRIGLYCERIDEMIC, ANTIHYPERGLYCEMIC, ANTI-ANGIOGENIC AND WOUND HEALING SUBSTITUDED INDOLEALKANOIC ACIDS | INST FOR PHARM DISCOVERY INC (US) | 2004-04-28 | — | — | EP | claimed |
| US-20030216452-A1 | Method of reducing serum glucose and triglyceride levels and for inhibiting angiogenesis using substitute indolealkanoic acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, INC. | 2003-11-20 | — | — | US | claimed |
| US-20030171405-A1 | Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY LLC., A CORPORATION OF THE STATE OF DELAWARE | 2003-09-11 | — | — | US | claimed |
| US-6555568-B1 | 3-(4,5,7-trifluorobenzothiazol-2-yl)methyl-indole-N-acetic acid, ethyl ester for example; treating angiogenesis, hyperglycemia, hyperlipidemia and chronic complications arising from diabetes mellitus | INSTITUTE FOR PHARMACEUTICAL DISCOVERY, L.L.C. | 2003-04-29 | — | — | US | claimed |
| US-6521659-B2 | 3-(4,5,7-trifluorobenzothiazol-2-yl) methyl-indole-N-acetic acid, ethyl ester and benazepril, for example; reduces serum glucose and triglycerides; treating angiogenesis, hyperglycemia, hyperlipidemia and diabetes mellitus | INSTITUTE FOR PHARMACEUTICAL DISCOVERY, LLC | 2003-02-18 | — | — | US | claimed |
| US-20030018053-A1 | Substituted indolealkanoic acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY LLC. | 2003-01-23 | — | — | US | claimed |
| US-6426344-B2 | INDOLEALKANOIC ACID DERIVATIVES INHIBITS ALDOSE REDUCTASE AND USEFUL FOR TREATING CHRONIC COMPLICATION ASSOCIATED WITH DIABETES MELLITUS INCLUDING DIABETIC CATARACTS, RETINOPATHY, NEPHROPATHY AND NEUROPATHY | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY LLC | 2002-07-30 | — | — | US | claimed |
| US-20010044437-A1 | Methods for reducing uric acid levels | INSTITUTE FOR PHARMACEUTICAL DISCOVERY LLC, THE | 2001-11-22 | — | — | US | claimed |
| US-20010041722-A1 | Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor | ALINEA PHARMACEUTICALS, INC. | 2001-11-15 | — | — | US | claimed |
| US-20010016661-A1 | Substituted indolealkanoic acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY | 2001-08-23 | — | — | US | claimed |
| US-6214991-B1 | 3-(4,5,7-TRIFLUOROBENZOTHIAZOL-2-YL)METHYL-INDOLE-N-ACETIC ACID, ETHYL ESTER FOR EXAMPLE; TREATING COMPLICATIONS OF DIABETES MELLITUS, SUCH AS CATARACTS, RETINOPATHY, NEPHROPATHY, AND NEUROPATHY | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, INC. | 2001-04-10 | — | — | US | claimed |
| US-20120270912-A1 | Substituted Indolealkanoic Acids | JONES MICHAEL LEE (US) | 2012-10-25 | — | — | US | disclosed |
| US-8163932-B2 | Substituted indolealkanoic acids | ALINEA PHARMACEUTICALS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20010041722-A1 | Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor | ALINEA PHARMACEUTICALS, INC. | 2001-11-15 | — | — | US | disclosed |
| US-20010016661-A1 | Substituted indolealkanoic acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY | 2001-08-23 | — | — | US | disclosed |
| US-6214991-B1 | 3-(4,5,7-TRIFLUOROBENZOTHIAZOL-2-YL)METHYL-INDOLE-N-ACETIC ACID, ETHYL ESTER FOR EXAMPLE; TREATING COMPLICATIONS OF DIABETES MELLITUS, SUCH AS CATARACTS, RETINOPATHY, NEPHROPATHY, AND NEUROPATHY | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, INC. | 2001-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010016661-A1 | Substituted indolealkanoic acids | GPR119, AANAT, AADAT | AKR1A1 475/4885AKR1B1 419/4885 |
| US-20030216452-A1 | Method of reducing serum glucose and triglyceride levels and for inhibiting angiogenesis using substitute indolealkanoic acids | LIPG, PNLIP, LIPA | AKR1A1 513/4885AKR1B1 475/4885 |
| US-20030018053-A1 | Substituted indolealkanoic acids | GPR119, AANAT, AADAT | AKR1A1 475/4885AKR1B1 419/4885 |
| US-20030171405-A1 | Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor | AGT, LIPG, ACE | AKR1A1 203/4885AKR1B1 185/4885 |
| US-20010044437-A1 | Methods for reducing uric acid levels | XDH, LIPA, OAT | AKR1A1 410/4885AKR1B1 207/4885 |
| US-20010041722-A1 | Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor | AGT, LIPG, ACE | AKR1A1 203/4885AKR1B1 185/4885 |
| US-20120270912-A1 | Substituted Indolealkanoic Acids | GPR119, AANAT, AADAT | AKR1A1 475/4885AKR1B1 419/4885 |
| US-20060074114-A1 | Methods of reducing serum glucose and triglyceride levels and for inhibiting angiogenesis using substituted indolealkanoic acids | LIPG, PNLIP, LIPA | AKR1A1 549/4885AKR1B1 499/4885 |
| US-20040235933-A1 | Substituted indolealkanoic acids | GPR119, AANAT, AADAT | AKR1A1 475/4885AKR1B1 419/4885 |
| US-20080214540-A1 | 3-[(phenyl or benzothiazol-2-yl)methyl]indole-N-acetic acids and esters; analgesics; aldose reductase inhibitors; diabetes complications including cataracts, retinopathy, nephropathy, and neuropathy; side effect reduction | AKR1C3, AKR1C2, AKR1B1 | AKR1A1 6/4885AKR1B1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.